The emerging antibiotic resistance of Gram-positive pathogens represents a significant challenge to the management of human infections. The novel oxazolidinone tedizolid demonstrates antimicrobial activity across a broad range of Gram-positive pathogens and greater potency than linezolid against wild-type and drugresistant pathogens, including linezolid-resistant Staphylococcus aureus strains possessing mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins L3 or L4. Strains harboring such mutations are also selected for much less frequently with tedizolid than with linezolid. In addition, tedizolid has a significant potency advantage over linezolid-resistant strains carrying the horizontally transferable cfr gene. Methylation of A2503 of 23S rRNA by the Cfr methyltransferase confers resistance to linezolid (and a variety of other 50S ribosomal subunit-targeted antibiotics) but not to tedizolid because of structural differences in A-ring C5 substituents between the 2 drugs. The greater potency and improved resistance profile of tedizolid provides the microbiologic basis for considering this molecule as an alternative to linezolid for the treatment of serious infections caused by Gram-positive pathogens.
oxazolidinone to enter the market (2000) , is approved for the treatment of infections associated with vancomycin-resistant Enterococcus faecium, community-acquired pneumonia due to Streptococcus pneumoniae, nosocomial pneumonia, and uncomplicated and complicated skin and skin structure infections, including diabetic foot infections [2, 6] . The clinical success of linezolid has driven considerable interest in developing new oxazolidinone molecules [6, 7] .
Collectively, multiple research programs have synthesized thousands of oxazolidinone analogs, resulting in more than a dozen development candidates, with structural modifications focused on the A-, C-, and Drings of the oxazolidinone. However, many of the resultant analogs have been discontinued because of a lack of potency, inadequate pharmacokinetics, or safety concerns such as unacceptable myelosuppression or high monoamine oxidase inhibitory activity [6, 7] . To date, 5 candidate molecules are undergoing mid-to late-stage clinical evaluation, including tedizolid phosphate, radezolid, 2 antitubercular compounds (sutezolid and AZD5847), and 1 anti-Clostridium difficile oxazolidinone, cadazolid.
DEVELOPMENT OF TEDIZOLID
Tedizolid phosphate (formerly known as torezolid phosphate, TR-701, DA-7218) is the inactive prodrug of the biologically active moiety tedizolid (TR-700, formerly torezolid, DA-7157), which has been shown to have potent antimicrobial activity against a wide range of Gram-positive aerobic and anaerobic bacterianotably MSSA, MRSA, methicillin-susceptible and -resistant coagulase-negative staphylococci (CoNS), vancomycin-resistant enterococci (VRE), S. pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae [5] . To enhance bioavailability, a series of prodrug formulations was evaluated for the formulations' physical chemistry properties and in vitro activity [6, 7] . Of these, a monophosphate ester was found to be highly watersoluble (>50 mg/mL), stable across a pH range of 3-7, and rapidly hydrolyzed by phosphatase activity, to retain better than 90% oral bioavailability [7] , and to have pharmacokinetic properties consistent with once-daily intravenous and oral dosing [5] .
Results from the first of 2 phase 3 trials (ESTABLISH 1) confirming similar clinical outcomes with 6 days of 200 mg once-a-day oral tedizolid to 10 days of twice-daily oral 600 mg linezolid have been published [8] . Initial results from the second phase 3 study comparing outcomes with intravenous formulations of tedizolid and linezolid have recently been released [9] . Plans are also underway to develop tedizolid for serious life-threatening hospitaland ventilator-associated pneumonias in light of encouraging pulmonary tedizolid distribution data in epithelial lining fluid and alveolar macrophages derived from healthy adults in a phase 1 clinical study [10] .
Protein Synthesis Inhibition
Oxazolidinones inhibit protein synthesis by binding to the 50S ribosomal subunit, blocking binding of aminoacyl-tRNA to the A-site of the peptidyl transferase center (PTC) [4, 6, 7] . X-ray crystallographic structures have shown that several drug classes have overlapping binding sites within the PTC and have identified several conserved ribonucleotides that interact (to varying degrees) with oxazolidinones [4, 6] . The PTC binding site for tedizolid is similar to the binding site for linezolid [4] (Figure 1 ), although the D-ring of tedizolid may engage additional sites on the ribosome and is likely responsible for the greater potency vs linezolid [6, 7, 11] . (SME) and postantibiotic subinhibitory effect (PA-SME) values of tedizolid were observed against staphylococci. These effects could contribute to growth inhibition at concentrations that would occur normally during trough drug exposure periods. Tedizolid SME and PA-SME values against staphylococci and enterococci were greater than those observed with linezolid. The prolonged SME and PA-SME observed with tedizolid relative to linezolid may be explained by differential protein inhibition profiles characterized via a macromolecular synthesis assay [13] . Methicillin resistance among staphylococci or vancomycin resistance among enterococci had no impact on the PAE, SME, or PA-SME of tedizolid or linezolid.
IN VITRO ACTIVITY OF TEDIZOLID
Subsequent in vitro studies have demonstrated that tedizolid is 4-to 16-fold more potent than linezolid against clinically relevant pathogens, including staphylococci, streptococci, and enterococci. An early evaluation of isolates from South Korea [14] reported a tedizolid MIC 90 ≤0.5 µg/mL for the Gram-positive isolates (including but not limited to MRSA and MSSA, vancomycin-susceptible and -resistant enterococci, S. pneumoniae, S. pyogenes, S. agalactiae, anaerobic Gram-positive bacilli, and Clostridium spp.) and demonstrated that tedizolid was more potent than either linezolid or vancomycin. A larger survey of 1063 isolates (including staphylococci, enterococci, streptococci, Moraxella catarrhalis, Haemophilus influenzae, and a variety of anaerobic bacterial species) confirmed these observations in isolates collected between 2005 and 2008 from study sites in the United States (80% of samples), Great Britain, France, Germany, and Australia [15] . Overall, tedizolid was 4-to 8-fold more potent against staphylococci than linezolid, (MIC 90 = 0.5 µg/mL for MSSA, MRSA, and community-acquired MRSA strains). Tedizolid was 2-to 8-fold more potent than vancomycin against staphylococci, 4-fold more potent than linezolid against enterococci and streptococci, and up to 4-fold more potent than linezolid against anaerobic species.
Brown and Traczewski [16] evaluated tedizolid in >1000 isolates representing 23 species or phenotypic groups and also showed that tedizolid was highly active against most Grampositive species, including all staphylococci (MIC 50 = 0.5 µg/mL, MIC 90 of ≤0.5 µg/mL), CoNS (MIC 50 = 0.25 µg/mL, MIC 90 of ≤0.5 µg/mL), enterococci (MIC 50 and MIC 90 ≤0.5 µg/mL), and streptococci (MIC 50 and MIC 90 ≤0.25 µg/mL). Based on these MIC 90 values, tedizolid was determined to be 4-fold more active than linezolid against S. aureus, CoNS, and enterococci, and 8-fold more active against streptococci. Tedizolid was moderately (2-fold) more active than linezolid against M. catarrhalis (MIC 90 4 µg/mL vs 8 µg/mL) and H. influenzae (MIC 90 16 µg/mL vs 32 µg/mL). In addition to determining the antimicrobial activity against a large collection of strains, Brown and Traczewski [16] determined the minimum bactericidal concentration for these strains. Tedizolid demonstrates bacteriostatic activity in vitro similar to linezolid and most other classes of drugs that inhibit protein synthesis.
The intracellular accumulation and activity of tedizolid has been evaluated using cultured human cell lines infected with clinical isolates. Lemaire and colleagues reported rapid accumulation of tedizolid into cultured human macrophages (THP-1), attaining a stable intracellular to extracellular ratio of approximately 10 (vs approximately 1-2 for linezolid) within 15 minutes of exposure [17] . In cultured macrophages or human umbilical vein endothelial cells infected with S. aureus, Listeria monocytogenes, or Legionella pneumophila, tedizolid was more active than linezolid (on a milligrams-per-liter basis) at decreasing colony-forming units [17] . Vera-Cabrera and colleagues [18] also compared the ability of linezolid and tedizolid to inhibit intracellular growth of Nocardia brasiliensis in the human THP-1 cell line. Cultured cells preloaded with Nocardia were exposed to concentrations of tedizolid or linezolid that encompassed a range of 0.25× MIC to 16× MIC. Tedizolid was fully active at inhibiting intracellular Nocardia growth when incubated at 0.25× MIC through 16× MIC. In contrast, intracellular Nocardia growth progressively declined when preloaded cells were exposed to increasing concentrations of linezolid. Even at 16× MIC, linezolid was less active than tedizolid in preventing intracellular Nocardia growth.
In a prospective, multiple-dose pharmacokinetic study, the pulmonary disposition of tedizolid was determined from samples collected by bronchoalveolar lavage after once-daily oral dosing of 200 mg tedizolid phosphate in 20 healthy volunteers [19] . Intracellular tedizolid concentration by alveolar macrophages was greater than 20 times the plasma-free drug concentration over a 24-hour period. Despite evidence for high intracellular drug accumulation, recent subcellular fractionation studies suggest that the drug accumulates in the cytosol, with little accumulation in mitochondrial or nuclear compartments [20] . Some adverse safety effects of linezolid have been linked to inhibition of mitochondrial, but not cytosolic, protein synthesis [21] .
Mechanisms of Linezolid Resistance
The first linezolid-resistant clinical isolates were 2 strains of E. faecium identified in the linezolid compassionate-use program and reported in 1999 [22] , before the drug's regulatory approval in 2000. After approval, additional linezolid-resistant strains were documented in enterococci and staphylococci isolated primarily from patients receiving prolonged therapy [23, 24] . Almost all known mechanisms of Gram-positive resistance to linezolid involve small conformational changes in the linezolid binding site, which adversely affect drug binding [6, 25] . Although oxazolidinone resistance remains rare in clinical settings [26] , several resistance mechanisms have been identified [25, 27] .
Point mutations in the 23S rRNA central loop of domain V (single or multilocation mutations within the same isolate) are anticipated based on in vitro drug exposure studies [6] and in clinical practice are often associated with prolonged antibiotic use or an ongoing clonal resistance outbreak [27] . Because pathogens such as S. aureus contain 5-6 copies of rRNA genes, the relationship between point mutations and observed resistance is also a function of the number of copies affected. This "gene dose" effect contributes to the low overall resistance in this class because multiple 23S alleles must possess mutations to achieve high levels of oxazolidinone resistance [6] . In linezolidresistant clinical isolates of S. aureus, E. faecalis, and E. faecium, MIC was positively correlated with the pyrosequence-confirmed copy number of genes containing the G2576T mutation; however, tedizolid retained greater potency than linezolid, even at the higher mutation copy numbers [28] (Table 1) . Interestingly, a linezolid-resistant isolate of S. aureus with the G2576T mutation in 2 of 5 alleles has been recently described in a patient with no prior exposure to oxazolidinones [29] . Serial passage in antibioticfree media did not alter the mutation prevalence. Mutations in genes encoding the ribosomal L3 and L4 proteins associated with the PTC of the ribosome have also been associated with linezolid resistance [27, 30] .
Beyond resistance conferred by chromosomally encoded point mutations, a horizontally transferable plasmid-borne ribosomal methyltransferase gene, cfr, also conveys resistance to linezolid [2, 11] . First identified in European veterinary isolates from the late 1990s [31] cfr was not found in human clinical isolates until 2005 when it was identified in Colombian MRSA isolate CM05, where it is coexpressed with the erythromycin ribosomal methylase B (ermB) gene [32, 33] . Recently, another linezolid-resistant MRSA that was isolated from a patient in Indianapolis, Indiana, in January 2005 was decribed [34] . This isolate, which predates the Colombian cfr isolate by 5 months, carries a single copy of the 23S rRNA gene mutation T2500A in addition to cfr. To date, the cfr gene has been identified in a variety of Gram-positive and Gram-negative species around the world [6] and will likely to continue to be disseminated because of a low cost of fitness [35] and selection by multiple drug classes. Acquisition of the cfr gene leads to broad cross-resistance to linezolid, as well as to phenicols, lincosamides, pleuromutilins, streptogramin A, and 16-memberring macrolide antibiotics [4, 6, 36] . Structure-activity relationship studies suggest that cfr-mediated methylation of A2503 of 23S rRNA interferes with linezolid binding due to steric hindrance of the acetamide group. However, the substitution of this side group with the smaller hydroxymethyl group in tedizolid is consistent with unobstructed ribosome binding, and thus activity is retained against cfr-positive isolates [37] . Additionally, a serial passage study of CM05 demonstrated that tedizolid did not select for the retention of the cfr gene whereas linezolid did, suggesting a therapeutic advantage for tedizolid when cfr-positive strains may be present [33] .
In Vitro Tedizolid Resistance Rates and Observed Mutation Types
The potential for S. aureus to develop reduced susceptibility to tedizolid was assessed in a spontaneous mutation frequency and serial passage study using ATCC 29213 (MSSA) and ATCC 33591 (MRSA) control strains [38] . The median mutation frequencies for tedizolid at 2× MIC were 1.1 × 10 −10 and 1.9 × 10 −10 for ATCC 29213 and ATCC 33591, respectively. These rates were approximately 16-fold lower than the corresponding mutation frequencies for linezolid in both strains. After 30 serial passages in the presence of tedizolid, the MIC value for ATCC 29213 remained constant (0.5 µg/mL), whereas the MIC for ATCC 33591 increased 8-fold (0.25 to 2.0 µg/mL) ( Figure 2 ). In contrast, serial passage of ATCC 29213 and ATCC 33591 in linezolid-containing media resulted in 64-and 32-fold increases in linezolid MIC values (2 µg/mL to 128 µg/mL; and 1 µg/mL to 32 µg/mL, respectively). Domain V mutations in 23S rRNA genes, including T2500A and a novel coupled T2571C/G2576 T mutation, were observed in tedizolid-selected serial passage mutants (Figure 2 ), whereas spontaneous mutants selected with tedizolid included T2500A and L3 mutations Gly155Arg, Gly155Arg/Met169Leu, and ΔPhe127-His146. All laboratory tedizolid-selected mutants generated in studies to date also exhibit cross-resistance with linezolid but have equivalent or lesser-fold MIC changes to tedizolid than to linezolid.
Activity of Tedizolid Against Resistant Pathogens of Clinical Origin
In 660 nonduplicate Staphylococcus isolates from bacteremic patients collected from 40 centers between 2004 and 2008, In evaluating a collection of staphylococci, including MRSA, and enterococcal isolates, Livermore and colleagues [28] observed that tedizolid was 4-fold more potent than linezolid against linezolid-susceptible isolates, with MIC values tightly clustered around 0.5 µg/mL vs 2.0 µg/mL for linezolid (Table 2) . For linezolid-resistant isolates (most attributed to G2576T mutations), tedizolid MIC values increased but were still substantially lower than those observed for linezolid (1-4 µg/mL range for tedizolid vs 8-64 µg/mL range for 10 linezolid-resistant MRSA and 6 CoNS isolates). Three of 36 linezolid-resistant enterococci isolates had tedizolid MIC values >4 µg/mL. Of these, 2 isolates were homozygous for G2576T, whereas the third had no mutations detected and was negative for the cfr gene. Shaw and colleagues [37] also demonstrated 8-to 16-fold greater potency of tedizolid over linezolid against linezolidresistant isolates of staphylococci (including MRSA and cfrpositive MRSA isolates), enterococci, and VRE (Table 3) . These data are consistent with an analysis of 120 clinical linezolidnonsusceptible staphylococci and enterococci possessing a variety of resistance mechanisms [40] . Tedizolid MIC values were ≤4 µg/mL vs approximately 90% of these isolates, with the greatest potency advantage over linezolid observed against cfrpositive strains.
Following earlier studies demonstrating the association of mutations in ribosomal protein L3 with linezolid resistance in laboratory-selected strains [38] , Locke and colleagues sought to determine whether similar mutations were present in clinical linezolid-resistant staphylococci. Analysis of rplC sequences in a panel of 11 linezolid-resistant isolates identified 2 L3 mutations (ΔSer145 and Ala157Arg) [30] . Consistent with MIC trends in the laboratory-selected L3 mutants, tedizolid maintained ≥8-fold potency advantage over linezolid against these clinical strains. Further work identified L3 mutations cooccurring in clinical linezolid-resistant S. aureus that also possessed the cfr gene [41] . A direct correlation was observed between the presence and severity of the L3 mutation and the level of linezolid resistance. Against these cfr-positive L3 mutant strains, tedizolid maintained a 32-fold MIC potency advantage over linezolid. Similar 32-fold tedizolid potency advantages over linezolid were observed in an MIC analysis of a large set of clinical linezolid-resistant staphylococci and enterococci possessing the cfr gene coupled with either L3 or 23S rRNA mutations [42] .
A recent phase 2 dose-ranging clinical trial confirmed the potency of tedizolid against isolates from patients with acute bacterial skin and skin structure infections (ABSSSIs) [43] . Baseline samples were evaluated at local laboratories, with confirmatory broth microdilution MIC testing performed at a central facility. Of 196 Gram-positive isolates (from 188 patients), 82% were S. aureus; of these, 76% were MRSA (99% Panton-Valentine leukocidin positive), and the remainder were MSSA (77% Panton-Valentine leukocidin positive). The MIC 50 and MIC 90 for tedizolid against both MRSA and MSSA isolates was 0.25 µg/mL compared with 1.0 µg/mL and 2.0 µg/mL, respectively, for linezolid (Table 4) .
SUSCEPTIBILITY TEST QUALITY CONTROL GUIDELINES
In vitro studies have shown that susceptibility to tedizolid can be determined using standard MIC and disk diffusion test methods [44, 45] . Multicenter studies to establish quality control ranges for the in vitro susceptibility testing of tedizolid were performed in accordance with guidelines established by the Clinical Laboratory Standards Institute [46] . The Clinical Adapted from Prokocimer et al [43] . Copyright © 2012, American Society for Microbiology. All Rights Reserved. Adapted with permission.
Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus. Laboratory Standards Institute-approved [47] quality control ranges are shown in Table 5 .
SUMMARY
Tedizolid was designed to improve on the microbiologic and clinical characteristics of linezolid. Comparative studies confirm that tedizolid offers more potent antimicrobial activity against a broad range of Gram-positive pathogens, including wild-type and linezolid-resistant strains (especially those possessing the cfr multidrug-resistance gene), with a lower frequency of mutations leading to drug resistance.
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